Author/Editor | Janež, Andrej | |
Title | Mesto tiazolidindionov v zdravljenju sladkorne bolezni tipa 2 | |
Translated title | The role of thiazolidinediones in the treatment of type 2 diabetes mellitus | |
Type | članek | |
Source | In: Židanik S, Tušek-Bunc K, editors. Medicinsko tehnični pripomočki. Zbornik 3. mariborski kongres družinske medicine; 2004 nov 26-27; Maribor. Ljubljana: Združenje zdravnikov družinske medicine SZD, | |
Publication year | 2004 | |
Volume | str. 24-5 | |
Language | slo | |
Abstract | Rosiglitazone is a member of the thiazolidinediones, a novel class of oral antidiabetic agents that improves glycemic control by reducing insulin resistance and reducing hepatic glucose output. Rosiglitazone binds and activates a nuclear receptor PPARgamma, which stimulates glucose transport in skeletal muscles and adipocytes. Numerous clinical studies wuh rosiglitazone have showed that these agents are effective at improving glycaemic control-with significant reduction in fasting and postprandial glucose and glycosylated haemoglobin HbA1c. A growing body of evidence also suggests that rosiglitazone have a positive impact on risk factors associated with an increased risk of cardiovascular disease, such as dyslipidaemia, abdominal obesity, hypertension, microalbuminuria and fibrinoloysis. | |
Descriptors | DIABETES MELLITUS, NON-INSULIN-DEPENDENT THIAZOLES METFORMIN |